Skip to content
value.today

Bellicum Pharmaceuticals, Inc.

Total raised
$115 M
3 rounds on record
Latest round
$94 M
Aug 2014
First round on record
Sep 2010
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Bellicum Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2014$94 MNo. 3$50 to $250 million

Bellicum Pharmaceuticals, Inc.: Raise no. 3, Aug 2014

Investors in this round

76 investors had bought by the notice of Sep 3, 2014: 76 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Bellicum Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$94 M of $94 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,141,250
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Annemarie K. Moseley · Executive Officer
  • David M. Spencer · Executive Officer
  • Ken K. Moseley · Executive Officer
  • Thomas J. Farrell · Executive Officer, Director
  • Dennis K. Stone · Director
  • Frank M. McGuyer · Director
  • James F. Brown · Director
  • Kevin M. Slawin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jefferies LLC (CRD 2347) · New York, New YorkSold in CA, CO, MA, MD, NJ, NY

Remarks in the notice

  • On the amounts: “The Total Offering Amount and Total Amount Sold includes $39,357,588 that may be received by the Issuer upon exercise of the warrants.”

Signed by Thomas J. Farrell, President & CEO. Source: SEC Form D, newest notice filed Sep 3, 2014. Read the notice at the SEC.

equity, optionsSEC
Nov 2011$20 MNo. 2$10 to $50 million

Bellicum Pharmaceuticals, Inc.: Raise no. 2, Nov 2011

Investors in this round

21 investors had bought by the notice of Oct 16, 2013: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Bellicum Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $35 M offered; $15 M still to sell
Smallest investment taken
$1,000,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Annemarie K. Moseley · Executive Officer
  • David M. Spencer · Executive Officer
  • Joseph K. Senesac · Executive Officer
  • Ken K. Moseley · Executive Officer
  • Kevin M. Slawin · Executive Officer, Director
  • Thomas J. Farrell · Executive Officer, Director
  • Dennis K. Stone · Director
  • Frank M. McGuyer · Director
  • James F. Brown · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas J. Farrell, President & CEO. Source: SEC Form D and 1 amendment, newest notice filed Oct 16, 2013. Read the notice at the SEC.

equitySEC
Sep 2010$1 MNo. 1Under $2 million

Bellicum Pharmaceuticals, Inc.: Raise no. 1, Sep 2010

Investors in this round

10 investors had bought by the notice of Oct 25, 2010: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Bellicum Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
$25,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Spencer · Executive Officer
  • Kevin Slawin · Executive Officer, Director
  • Thomas Farrell · Executive Officer, Director
  • Frank McGuyer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas James Farrell, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 25, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Bellicum Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2014).

    SEC Form D · Sep 2014

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2014

That is all the official record says: Bellicum Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Bellicum Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Baker Bros. Advisors (GP) LLCFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Baker Bros. Advisors LPFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2023)SEC Form 3
David M. SpencerPersonnot statednot statedHeld Series C preferred stock (Form 3, 2014)SEC Form 3
Kevin M. SlawinPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2014)SEC Form 3
McGuyer Investments Ltd.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Remeditex Ventures LLCVenture capitalnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Thomas J. FarrellPersonnot statednot statedHeld Series B and C preferred stock, director (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 76 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Bellicum Pharmaceuticals, Inc.
NameRoleNamed in
Annemarie K. MoseleyExecutive officerSep 2014
David M. SpencerExecutive officerSep 2014
Ken K. MoseleyExecutive officerSep 2014
Thomas J. FarrellExecutive officerSep 2014
Joseph K. SenesacExecutive officerOct 2013
Kevin M. SlawinExecutive officerOct 2013
David SpencerExecutive officerOct 2010
Kevin SlawinExecutive officerOct 2010
Thomas FarrellExecutive officerOct 2010
Dennis K. StoneDirectorSep 2014
Frank M. McGuyerDirectorSep 2014
James F. BrownDirectorSep 2014
Kevin M. SlawinDirectorSep 2014
Thomas J. FarrellDirectorSep 2014
Frank McGuyerDirectorOct 2010
Kevin SlawinDirectorOct 2010
Thomas FarrellDirectorOct 2010